OctoPlus expands development agreement with ESBATech on controlled release product for ophthalmic indications
The project includes process development, scale-up and manufacturing for pre-clinical studies. Financial details are not disclosed, but the project will make a material contribution to our annual revenues in 2011. In addition to Locteron®, this programme will be part of our portfolio of projects utilising our proprietary technologies.
This drug delivery technology evaluation project started in 2009. OctoPlus evaluated the feasibility of a controlled release formulation that combines a proprietary eye care ingredient of ESBATech with our drug delivery technology PolyActive®.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.